MCID: SLP001
MIFTS: 48

Sleeping Sickness

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Sleeping Sickness

MalaCards integrated aliases for Sleeping Sickness:

Name: Sleeping Sickness 12 52 53 58 3 15
African Trypanosomiasis 12 74 58 3 15 71 32
Trypanosomiasis, Human East-African 52
Human African Trypanosomiasis 17
African Sleeping Sickness 12
Trypanosomiasis, African 43
Trypanosomiasis African 54

Characteristics:

Orphanet epidemiological data:

58
african trypanosomiasis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:10112
ICD9CM 34 086.5
MeSH 43 D014353
NCIt 49 C84541
SNOMED-CT 67 27031003 78940002
ICD10 32 B56 B56.9
MESH via Orphanet 44 D014353
ICD10 via Orphanet 33 B56.0 B56.1 B56.9
UMLS via Orphanet 72 C0041228
Orphanet 58 ORPHA3385
UMLS 71 C0041228

Summaries for Sleeping Sickness

NINDS : 53 Encephalitis lethargica is a disease characterized by high fever, headache, double vision, delayed physical and mental response, and lethargy. In acute cases, patients may enter coma. Patients may also experience abnormal eye movements, upper body weakness, muscular pains, tremors, neck rigidity, and behavioral changes including psychosis. The cause of encephalitis lethargica is unknown. Between 1917 to 1928, an epidemic of encephalitis lethargica spread throughout the world, but no recurrence of the epidemic has since been reported. Postencephalitic Parkinson's disease may develop after a bout of encephalitis-sometimes as long as a year after the illness.

MalaCards based summary : Sleeping Sickness, also known as african trypanosomiasis, is related to trypanosomiasis and leishmaniasis. An important gene associated with Sleeping Sickness is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are African trypanosomiasis and Glutathione metabolism. The drugs Ornithine and Nifurtimox have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A trypanosomiasis that results from infection by Trypanosoma brucei and gambiense, which is transmitted by the bite of an infected tsetse fly (Glossina spp). The symptoms include fever, headache, joint pain, itching, confusion, sensory disturbances, poor coordination and sleep disturbances.

CDC : 3 African Trypanosomiasis, also known as "sleeping sickness", is caused by microscopic parasites of the species Trypanosoma brucei. It is transmitted by the tsetse fly (Glossina species), which is found only in rural Africa. Although the infection is not found in the United States, historically, it has been a serious public health problem in some regions of sub-Saharan Africa. Currently, about 10,000 new cases each year are reported to the World Health organization; however, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is curable with medication, but is fatal if left untreated.

Wikipedia : 74 African trypanosomiasis, also known as African sleeping sickness, is an insect-borne parasitic disease... more...

Related Diseases for Sleeping Sickness

Diseases related to Sleeping Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 31.7 ODC1 NOS2 IL6 IL10 HPR HP
2 leishmaniasis 30.9 SRM PGD ODC1 NOS2 MDH2 IL6
3 chagas disease 30.8 SRM ODC1 NOS2 IL6 IL10 GSR
4 orchitis 30.7 IL6 IL10 H2AC18
5 visceral leishmaniasis 30.7 PGD NOS2 IL10
6 dysentery 30.7 TF IL6 IL10 HP
7 filariasis 30.6 NOS2 IL6 IL10
8 acquired immunodeficiency syndrome 30.5 NOS2 IL6 IL10 APOA1
9 exanthem 30.5 IL6 IL10 H2AC18
10 deficiency anemia 30.5 TF IL6 HP H2AC18 GSR
11 bacterial infectious disease 30.4 PRODH IL6 IL10 H2AC18
12 nervous system disease 30.4 PRODH NOS2 IL6 H2AC18
13 malaria 30.3 SRM ODC1 NOS2 IL6 IL10 HP
14 parasitic protozoa infectious disease 30.3 PRODH IL6 IL10 HP H2AC18 APOL1
15 toxoplasmosis 30.3 NOS2 IL6 IL10
16 placenta disease 30.3 PRODH IL6 H2AC18
17 central nervous system disease 30.2 PRODH NOS2 IL6 H2AC18
18 eye disease 30.1 PRODH IL6 IL10 H2AC18 GAPDH APOA1
19 kidney disease 30.0 TF NOS2 IL6 HP GSR APOL1
20 trypanosomiasis, human west-african 11.4
21 von economo's disease 11.4
22 eastern equine encephalitis 11.2
23 spotted fever rickettsiosis 10.6 NOS2 IL10
24 bronchopneumonia 10.6 IL6 IL10 HP
25 endometrial disease 10.6 IL6 IL10 HP
26 autoimmune disease of blood 10.6 IL6 IL10 HP
27 trachoma 10.6 IL6 IL10 HP
28 syndromic x-linked intellectual disability snyder type 10.6 SRM ODC1 AMD1
29 rheumatic fever 10.6 IL6 IL10 HP
30 acute transverse myelitis 10.6 IL6 IL10 APOA1
31 transverse myelitis 10.6 IL6 IL10 APOA1
32 bacterial sepsis 10.6 NOS2 IL6 IL10
33 acute myocarditis 10.6 IL6 IL10 H2AC18
34 streptococcus pneumonia 10.6 IL6 IL10 H2AC18
35 herpangina 10.6 IL6 IL10 H2AC18
36 vaginal disease 10.6 IL6 IL10 H2AC18
37 listeriosis 10.6 IL6 IL10 H2AC18
38 coccidiosis 10.6 IL6 IL10 H2AC18
39 anus disease 10.6 IL6 IL10 H2AC18
40 anhaptoglobinemia 10.6 HPR HP
41 extrinsic allergic alveolitis 10.6 IL6 IL10 HP
42 autoimmune disease of urogenital tract 10.6 IL6 IL10 H2AC18
43 rectal disease 10.6 IL6 IL10 H2AC18
44 autoimmune disease of endocrine system 10.6 IL6 IL10 H2AC18
45 spinal cord disease 10.6 IL6 IL10 H2AC18
46 combined t cell and b cell immunodeficiency 10.6 IL6 IL10 H2AC18
47 extrinsic cardiomyopathy 10.6 IL6 IL10 H2AC18
48 hypersensitivity reaction type iv disease 10.5 IL6 IL10 H2AC18
49 reactive arthritis 10.5 IL6 IL10 HP
50 commensal bacterial infectious disease 10.5 IL6 IL10 H2AC18

Graphical network of the top 20 diseases related to Sleeping Sickness:



Diseases related to Sleeping Sickness

Symptoms & Phenotypes for Sleeping Sickness

GenomeRNAi Phenotypes related to Sleeping Sickness according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.84 NOS2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.84 H2AC18 NOS2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.84 ODC1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.84 NOS2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.84 NOS2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.84 PRODH
7 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.84 PRODH
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.84 H2AC18
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 ODC1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.84 PRODH
11 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.84 ODC1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.84 NOS2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.84 PRODH
14 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.84 PRODH
15 Increased shRNA abundance (Z-score > 2) GR00366-A-200 9.84 PRODH
16 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.84 ODC1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.84 PRODH
18 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.84 ODC1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.84 PRODH
20 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.84 H2AC18
21 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.84 NOS2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.84 PRODH
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.84 NOS2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.84 PRODH
25 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.84 H2AC18
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.84 NOS2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.84 PRODH
28 Increased shRNA abundance (Z-score > 2) GR00366-A-90 9.84 NOS2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.84 H2AC18 NOS2 ODC1 PRODH

Drugs & Therapeutics for Sleeping Sickness

Drugs for Sleeping Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
2 Nifurtimox Investigational Phase 3 23256-30-6
3 Melarsoprol Investigational Phase 3 494-79-1
4 polysaccharide-K Phase 2, Phase 3
5 Antibodies Phase 2, Phase 3
6 Immunoglobulins Phase 2, Phase 3
7 Anti-Infective Agents Phase 3
8 Antiparasitic Agents Phase 3
9 Antiprotozoal Agents Phase 3
10
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
11
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
12
Permethrin Approved, Investigational Phase 2 52645-53-1 40326
13
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
14
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
15
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
16
Pafuramidine Investigational Phase 2 186953-56-0
17 Antifungal Agents Phase 2
18 Insect Repellents Phase 2
19 Protective Agents Phase 2
20 Vitamins Phase 2
21 Trace Elements Phase 2
22 Micronutrients Phase 2
23 Antioxidants Phase 2
24 Nutrients Phase 2
25
Dopamine Approved 51-61-6, 62-31-7 681
26
Methylphenidate Approved, Investigational 113-45-1 4158
27
Caffeine Approved 58-08-2 2519
28
Modafinil Approved, Investigational 68693-11-8 4236
29 Immunoglobulin G
30 Immunoglobulin M
31 Immunologic Factors
32 Neurotransmitter Agents
33 Dopamine Uptake Inhibitors
34 Dopamine Agents
35 Central Nervous System Stimulants
36 Cytochrome P-450 CYP3A Inducers
37 Phosphodiesterase Inhibitors

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Unknown status NCT02184689 Phase 2, Phase 3 fexinidazole
3 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Unknown status NCT02169557 Phase 2, Phase 3 Fexinidazole
4 Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
5 Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
6 Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo Completed NCT01589289 Phase 3
7 Efficacy and Safety Study of SCYX-7158 in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study Recruiting NCT03087955 Phase 2, Phase 3 SCYX 7158
8 An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Recruiting NCT03025789 Phase 3 Fexinidazole
9 Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial Recruiting NCT03974178 Phase 2, Phase 3 Fexinidazole
10 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring Recruiting NCT04099628 Phase 2, Phase 3
11 Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
12 Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
13 Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease. Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
14 Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
15 Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
16 A Within-subject Laboratory and Field Trial to Test the Use of Commercially Available Insect Repellents Against Contact From Musca Sorbens, the Putative Vector of Trachoma Suspended NCT03813069 Phase 2
17 Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia Terminated NCT00184054 Phase 2 Arsenic Trioxide (ATO);Ascorbic Acid
18 Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers Completed NCT00982904 Phase 1 Fexinidazole/Placebo
19 Randomized, Open Study to Assess the Impact of Two Different Types of Food on the Relative Bioavailability of Fexinidazole Tablets After Single Oral Dose in Healthy Male Volunteers Completed NCT01340157 Phase 1 Fexinidazole
20 A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition Completed NCT02571062 Phase 1 Fexinidazole
21 Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers Completed NCT01533961 Phase 1 SCYX-7158;Placebo
22 Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers. Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
23 Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan Completed NCT01766830
24 Effects of Modafinil, Caffeine and Methylphenidate on Functional Brain Activity and Cognitive Performance in Healthy Volunteers: a Randomized, Placebo-controlled, Double-blind fMRI Study Completed NCT02071615 Methylphenidate 20 mg tablet given once by mouth;modafinil 200mg tablet given once by mouth;caffein 200mg tablet given once by mouth;placebo
25 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses Completed NCT02439918
26 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Recruiting NCT03356665
27 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure Active, not recruiting NCT03112655
28 Prospective Evaluation of a Rapid Diagnostic Test to Screen for Gambiense Human African Trypanosomiasis and Diagnose Plasmodium Falciparum Malaria Not yet recruiting NCT03394976

Search NIH Clinical Center for Sleeping Sickness

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Eflornithine
Eflornithine Hydrochloride

Cochrane evidence based reviews: trypanosomiasis, african

Genetic Tests for Sleeping Sickness

Anatomical Context for Sleeping Sickness

MalaCards organs/tissues related to Sleeping Sickness:

40
Testes, Brain, T Cells, Eye, Kidney, Heart, B Cells

Publications for Sleeping Sickness

Articles related to Sleeping Sickness:

(show top 50) (show all 4219)
# Title Authors PMID Year
1
Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase. 54 61
20220141 2010
2
Genetic validation of aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets in Trypanosoma brucei. 54 61
19748525 2010
3
Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. 54 61
17643344 2007
4
Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. 54 61
17610127 2007
5
Synthesis and biological evaluation of phosphate prodrugs of 4-phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphogluconate dehydrogenase. 54 61
17615587 2007
6
A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 1-amino-oxy-3-aminopropane. 54 61
17407445 2007
7
Pyridoxal 5'-phosphate enzymes as targets for therapeutic agents. 54 61
17504214 2007
8
In vitro generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei. 54 61
16896212 2006
9
The trypanosome lytic factor of human serum and the molecular basis of sleeping sickness. 54 61
15217727 2004
10
The detection of bovine lactoferrin binding protein on Trypanosoma brucei. 54 61
15240935 2004
11
Clinical and neuroinflammatory responses to meningoencephalitis in substance P receptor knockout mice. 54 61
12805119 2003
12
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa. 54 61
12653650 2003
13
Transferrin coupled azanthraquinone enhances the killing effect on trypanosomes. The role of lysosomal mannosidase. 54 61
12514955 2002
14
Identification and functional characterization of thioredoxin from Trypanosoma brucei brucei. 54 61
10713060 2000
15
The transferrin receptor of Trypanosoma brucei. 54 61
11227758 2000
16
Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. 54 61
9822549 1998
17
Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity. 54 61
9174360 1997
18
Synthesis and structure-activity relationships of analogs of 2'-deoxy-2'-(3-methoxybenzamido)adenosine, a selective inhibitor of trypanosomal glycosomal glyceraldehyde-3-phosphate dehydrogenase. 54 61
7562915 1995
19
Polyamines as targets for therapeutic intervention. 54 61
7598507 1995
20
Selective inhibition of trypanosomal glyceraldehyde-3-phosphate dehydrogenase by protein structure-based design: toward new drugs for the treatment of sleeping sickness. 54 61
7932587 1994
21
Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. 54 61
8347171 1993
22
New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. 61
31879061 2020
23
C6-O-alkylated 7-deazainosine nucleoside analogues: Discovery of potent and selective anti-sleeping sickness agents. 61
31931339 2020
24
Crystal structure of the N-terminal domain of the trypanosome flagellar protein BILBO1 reveals a ubiquitin fold with a long structured loop for protein binding. 61
31882537 2020
25
Lipophilic Guanylhydrazone Analogues As Promising Trypanocidal Agents: An Extended SAR Study. 61
32039675 2020
26
Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach. 61
32033395 2020
27
The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History. 61
31963784 2020
28
Monitoring the presence of trypanosomes' DNA - Including Trypanosoma brucei gambiense DNA - From the midguts of riverine Glossina trapped in the south east outskirts of Kinshasa City (Democratic Republic of Congo). 61
31689541 2020
29
Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association. 61
31906333 2020
30
Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo. 61
31986140 2020
31
Blood signatures for second stage human African trypanosomiasis: a transcriptomic approach. 61
32000760 2020
32
A role for hepcidin in the anemia caused by Trypanosoma brucei infection. 61
31919087 2020
33
Crystal structure of TbEsa1 presumed Tudor domain from Trypanosoma brucei. 61
31747559 2020
34
Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole. 61
32012658 2020
35
In cellulo crystallization of Trypanosoma brucei IMP dehydrogenase enables the identification of genuine co-factors. 61
32001697 2020
36
A Unified Total Synthesis of the Actinoallolides, a Family of Potent Anti-Trypanosomal Macrolides. 61
31743574 2020
37
Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? 61
31952121 2020
38
Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment. 61
31940846 2020
39
mSphere of Influence: Expanding the CRISPR Sphere with Single-Locus Proteomics. 61
31969475 2020
40
Screening for Small Molecule Modulators of Trypanosoma brucei Hsp70 Chaperone Activity Based upon Alcyonarian Coral-Derived Natural Products. 61
32012664 2020
41
Design and synthesis of α-phenoxy-N-sulfonylphenyl acetamides as Trypanosoma brucei Leucyl-tRNA synthetase inhibitors. 61
31732256 2020
42
A simple, robust, and affordable bioluminescent assay for drug discovery against infective African trypanosomes. 61
31958156 2020
43
The use of Sulfonamide Derivatives in the Treatment of Trypanosomatid Parasites including Trypanosoma cruzi, Trypanosoma brucei, and Leishmania ssp. 61
31218962 2020
44
Whose Elimination? Frontline Workers' Perspectives on the Elimination of the Human African Trypanosomiasis and Its Anticipated Consequences. 61
31906341 2020
45
Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis. 61
31846577 2020
46
Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC). 61
31961872 2020
47
Centering Patient Expectations of a Novel Home-Based Oral Drug Treatment among T. b. rhodesiense Human African Trypanosomiasis Patients in Uganda. 61
31973101 2020
48
Associations of mental disorders and neurotropic parasitic diseases: a meta-analysis in developing and emerging countries. 61
31805904 2019
49
Overview of the role of kinetoplastid surface carbohydrates in infection and host cell invasion: prospects for therapeutic intervention. 61
31603063 2019
50
Evolutionary divergent PEX3 is essential for glycosome biogenesis and survival of trypanosomatid parasites. 61
31369765 2019

Variations for Sleeping Sickness

Expression for Sleeping Sickness

Search GEO for disease gene expression data for Sleeping Sickness.

Pathways for Sleeping Sickness

Pathways related to Sleeping Sickness according to KEGG:

36
# Name Kegg Source Accession
1 African trypanosomiasis hsa05143

GO Terms for Sleeping Sickness

Cellular components related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TF IL6 IL10 HSPA8 HPR HP
2 extracellular exosome GO:0070062 9.7 TF PGD MDH2 HSPA8 HPR HP
3 spherical high-density lipoprotein particle GO:0034366 9.16 HPR APOA1
4 blood microparticle GO:0072562 9.1 TF HSPA8 HPR HP APOL1 APOA1

Biological processes related to Sleeping Sickness according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.88 PRODH PGD NOS2 MDH2 GSR GAPDH
2 cellular protein metabolic process GO:0044267 9.73 TF IL6 APOL1 APOA1
3 response to organic substance GO:0010033 9.65 IL10 HPR HP
4 receptor-mediated endocytosis GO:0006898 9.56 HPR HP APOL1 APOA1
5 positive regulation of cell death GO:0010942 9.5 PRODH HPR HP
6 acute inflammatory response GO:0002526 9.49 HPR HP
7 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.46 IL10 APOA1
8 negative regulation of cytokine secretion involved in immune response GO:0002740 9.37 IL10 APOA1
9 spermidine biosynthetic process GO:0008295 9.16 SRM AMD1
10 polyamine biosynthetic process GO:0006596 9.13 SRM ODC1 AMD1
11 polyamine metabolic process GO:0006595 8.8 SRM ODC1 AMD1

Molecular functions related to Sleeping Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.43 PRODH PGD NOS2 MDH2 GSR GAPDH
2 hemoglobin binding GO:0030492 9.16 HPR HP
3 NADP binding GO:0050661 8.92 PGD NOS2 GSR GAPDH

Sources for Sleeping Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....